GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Quick Ratio

Anixa Biosciences (Anixa Biosciences) Quick Ratio : 15.19 (As of Jan. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Anixa Biosciences's quick ratio for the quarter that ended in Jan. 2024 was 15.19.

Anixa Biosciences has a quick ratio of 15.19. It generally indicates good short-term financial strength.

The historical rank and industry rank for Anixa Biosciences's Quick Ratio or its related term are showing as below:

ANIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.34   Med: 7.39   Max: 30.67
Current: 15.19

During the past 13 years, Anixa Biosciences's highest Quick Ratio was 30.67. The lowest was 0.34. And the median was 7.39.

ANIX's Quick Ratio is ranked better than
89.75% of 1551 companies
in the Biotechnology industry
Industry Median: 3.51 vs ANIX: 15.19

Anixa Biosciences Quick Ratio Historical Data

The historical data trend for Anixa Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Quick Ratio Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.11 7.88 28.35 14.83 12.50

Anixa Biosciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.81 17.83 14.22 12.50 15.19

Competitive Comparison of Anixa Biosciences's Quick Ratio

For the Biotechnology subindustry, Anixa Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Quick Ratio falls into.



Anixa Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Anixa Biosciences's Quick Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Quick Ratio (A: Oct. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(25.356-0)/2.028
=12.50

Anixa Biosciences's Quick Ratio for the quarter that ended in Jan. 2024 is calculated as

Quick Ratio (Q: Jan. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(25.219-0)/1.66
=15.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anixa Biosciences  (NAS:ANIX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Anixa Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747